Paysign, Inc. (NASDAQ: PAYS) reported Q4 EPS of $0.01, in-line with the analyst estimate of $0.01. Revenue for the quarter came in at $7.3 million versus the consensus estimate of $7.39 million.

• Fourth-quarter adjusted EBITDA of $0.8 million, or diluted adjusted EBITDA per share of $0.01
• Fourth-quarter net loss of $4.3 million, or diluted earnings per share (EPS) of ($0.09), which includes a $4.0 million tax provision for recording a valuation on our deferred tax asset which remains available for future benefit
• Fourth-quarter total revenues of $7.3 million, a decrease of $2.5 million from fourth-quarter 2019
• Fourth-quarter gross dollar load volume declined 2.2% versus the year-ago period and increased 15.9% versus the previous quarter
• Fourth-quarter purchase volume decreased 12.0% versus the year-ago period and increased 14.4% versus the previous quarter

“2020 was a difficult year for our business due to the COVID-19 pandemic, as it negatively impacted our clients in the pharma and plasma industries. The month of May marked the low point for our plasma business and we have continued to see improvements throughout the year as states loosen restrictions on businesses. While COVID-19 and government stimulus measures will likely continue to impact our business into 2021, we remain cautiously optimistic that our business will continue to rebound as vaccinations become more prevalent and business restrictions are lifted,” said Paysign CEO Mark Newcomer. “During the year we added 55 new plasma programs and experienced a net growth in card programs of 61. With $7.8 million of unrestricted cash and zero debt on our balance sheet, the company remains well-capitalized and positioned to weather any further impacts from the pandemic.”

For earnings history and earnings-related data on Paysign, Inc. (PAYS) click here.